Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Liabilities from Discontinued Operations (2016)

Historic Liabilities from Discontinued Operations for Protalix BioTherapeutics (PLX) over the last 3 years, with Q2 2016 value amounting to $293000.0.

  • Protalix BioTherapeutics' Liabilities from Discontinued Operations changed N/A to $293000.0 in Q2 2016 from the same period last year, while for Jun 2016 it was $293000.0, marking a year-over-year change of. This contributed to the annual value of $1.6 million for FY2015, which is 9703.2% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Liabilities from Discontinued Operations stood at $293000.0 for Q2 2016.
  • Protalix BioTherapeutics' 5-year Liabilities from Discontinued Operations high stood at $52.8 million for Q4 2014, and its period low was $128000.0 during Q1 2016.
  • Its 3-year average for Liabilities from Discontinued Operations is $13.7 million, with a median of $930500.0 in 2015.
  • Data for Protalix BioTherapeutics' Liabilities from Discontinued Operations shows a peak YoY increase of 9703.2% (in 2015) and a maximum YoY decrease of 9703.2% (in 2015) over the last 5 years.
  • Quarter analysis of 3 years shows Protalix BioTherapeutics' Liabilities from Discontinued Operations stood at $52.8 million in 2014, then plummeted by 97.03% to $1.6 million in 2015, then plummeted by 81.31% to $293000.0 in 2016.
  • Its Liabilities from Discontinued Operations was $293000.0 in Q2 2016, compared to $128000.0 in Q1 2016 and $1.6 million in Q4 2015.